Somebody posted on another thread the approval rate for ODD rare disease NDAs is 94%, so there's your risk quantified.
I would say, however, that the 6% that fail would have issues with their clinical data whereas the Acadia data is compelling with vocal patient advocacy support, so I'm very confident.
My opinions only of course, DYOR.
NEU Price at posting:
$5.72 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)